Clinical Trials Directory

Trials / Completed

CompletedNCT06159959

Carbetocin in the Prevention of Primary Postpartum Haemorrhage

Carbetocin in the Prevention of Primary Postpartum Haemorrhage in Obese Versus Non-obese Women Undergoing Elective Cesarean Section

Status
Completed
Phase
Study type
Observational
Enrollment
244 (actual)
Sponsor
Ministry of Health and Population, Egypt · Other Government
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

Postpartum haemorrhage (PPH) ranks as the first cause of maternal mortality in developing countries and it is the cause of 25% of maternal deaths worldwide. Carbetocin is a long-acting synthetic octapeptide analogue of oxytocin with agonist properties. Like oxytocin, carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions and increased uterine tone.

Detailed description

Postpartum hemorrhage is defined as a blood loss more than 500 ml, and serious PPH as a blood loss more than 1,000 ml. It is a common maternal morbidity in high-resource countries and is trending upward and prevention of postpartum haemorrhage is, therefore, of great importance for improved maternal health care. Although two-thirds of the PPH cases occur in women without predisposing factors, there are several risk factors for PPH. The most frequent cause of PPH is uterine atony, contributing up to 80 % of the PPH cases . Studies investigating effect of increased BMI on birth outcomes in a general obstetric population revealed an association between obesity and PPH. The overall increased risk of postpartum hemorrhage among obese women was 8-13%, depending on obesity class. The risk of postpartum haemorrhage is much higher for women undergoing Cesarean section, particularly in developing countries, where the majority of operations are carried out as an emergency procedure. Maternal obesity is associated with an elevated risk of intrapartum cesarean section, mainly due to reduced uterine contractility culminating in failure to progress in labor . Up to date, which uterotonic agent suitable for prophylactic use is being debated and literature lacks of clear endpoints on this item . The most routinely and widely used uterotonic agent for preventing postpartum haemorrhage is oxytocin, but it only has a half-life of 4-10 min. So, it must be administered as a continuous intravenous infusion to achieve sustained uterotonic activity, which is inconvenient and makes dosing errors a possibility.

Conditions

Interventions

TypeNameDescription
DRUGCarbetocinTo assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.

Timeline

Start date
2023-01-01
Primary completion
2023-10-01
Completion
2023-10-30
First posted
2023-12-07
Last updated
2023-12-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06159959. Inclusion in this directory is not an endorsement.